Dr. Roach Warns Oxybutynin May Raise Dementia Risk 1% to 5%, Urges CKD Diet Steps
Updated
Updated · Detroit News · Jul 17
Dr. Roach Warns Oxybutynin May Raise Dementia Risk 1% to 5%, Urges CKD Diet Steps
2 articles · Updated · Detroit News · Jul 17
Summary
Long-term daily oxybutynin use for 3 years or more may slightly raise dementia risk, with estimates ranging from under 1% to 5%, Dr. Roach said.
For overactive bladder, he said trospium likely carries the lowest dementia risk among anticholinergics, while newer beta-3 agonists such as mirabegron and vibegron offer similar efficacy without known dementia risk.
For chronic kidney disease, he said supplements like pumpkin seed oil or cinnamon lack good evidence, and that treatment should center on diet, blood pressure control and diabetes management.
Less than 2,000 mg of sodium daily, about 0.8 grams of protein per day as a starting point, and a mostly plant-based diet can help lower kidney failure risk in people with diabetes and CKD.
An eGFR of 52 and creatinine of 1.39 mg/dL fit a common CKD picture in older adults, where drugs such as Jardiance, ACE inhibitors, ARBs, finerenone and GLP-1 medicines can slow progression.